253 related articles for article (PubMed ID: 29716549)
1. LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data.
Kim SI; Lee JW; Lee N; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
BMC Cancer; 2018 May; 18(1):494. PubMed ID: 29716549
[TBL] [Abstract][Full Text] [Related]
2.
Holst F; Werner HMJ; Mjøs S; Hoivik EA; Kusonmano K; Wik E; Berg A; Birkeland E; Gibson WJ; Halle MK; Trovik J; Cherniack AD; Kalland KH; Mills GB; Singer CF; Krakstad C; Beroukhim R; Salvesen HB
Clin Cancer Res; 2019 Jan; 25(1):334-345. PubMed ID: 30442683
[TBL] [Abstract][Full Text] [Related]
3. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Zhou M; Zhang Z; Zhao H; Bao S; Sun J
BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
[TBL] [Abstract][Full Text] [Related]
4. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
5. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
Zhang Q; Xia T; Qi C; Du J; Ye C
BMC Cancer; 2022 Jan; 22(1):77. PubMed ID: 35042454
[TBL] [Abstract][Full Text] [Related]
6. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and Genomic Analysis of
Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
[TBL] [Abstract][Full Text] [Related]
8. Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma.
Depreeuw J; Stelloo E; Osse EM; Creutzberg CL; Nout RA; Moisse M; Garcia-Dios DA; Dewaele M; Willekens K; Marine JC; Matias-Guiu X; Amant F; Lambrechts D; Bosse T
Clin Cancer Res; 2017 Dec; 23(23):7232-7241. PubMed ID: 28939739
[No Abstract] [Full Text] [Related]
9. A 14-Methylation-Driven Differentially Expressed RNA as a Signature for Overall Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
Zeng Z; Cheng J; Ye Q; Zhang Y; Shen X; Cai J; Li M
DNA Cell Biol; 2020 Jun; 39(6):975-991. PubMed ID: 32397815
[TBL] [Abstract][Full Text] [Related]
10. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of ESRRA in Endometrial Cancer.
Wang S; Huo X
Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
[TBL] [Abstract][Full Text] [Related]
12. Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression.
Banas T; Pitynski K; Okon K; Winiarska A
BMC Cancer; 2018 Apr; 18(1):418. PubMed ID: 29653556
[TBL] [Abstract][Full Text] [Related]
13. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of genomic instability-derived long non-coding RNA signature of endometrial cancer.
Huo XL; Wang SF; Yang Q; Yu XL; Gu T; Hua HX; Yang M; Bai LL; Zhang XL
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):96-101. PubMed ID: 35181055
[TBL] [Abstract][Full Text] [Related]
15. A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma.
Wang Y; Xu M; Yang Q
Curr Probl Cancer; 2019 Apr; 43(2):167-176. PubMed ID: 29567372
[TBL] [Abstract][Full Text] [Related]
16. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
[TBL] [Abstract][Full Text] [Related]
17. KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
Saglam O; Tang Z; Tang G; Medeiros LJ; Toruner GA
PLoS One; 2020; 15(9):e0238477. PubMed ID: 32877461
[TBL] [Abstract][Full Text] [Related]
18. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
[TBL] [Abstract][Full Text] [Related]
19. Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.
Hotton J; Agopiantz M; Leroux A; Charra-Brunaud C; Marie B; Busby-Venner H; Morel O; Guéant JL; Vignaud JM; Battaglia-Hsu SF; Gauchotte G
Virchows Arch; 2018 Apr; 472(4):623-633. PubMed ID: 29243125
[TBL] [Abstract][Full Text] [Related]
20. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.
Mauland KK; Wik E; Hoivik EA; Kusonmano K; Halle MK; Berg A; Haugland HK; Øyan AM; Kalland KH; Stefansson IM; Akslen LA; Krakstad C; Trovik J; Werner HM; Salvesen HB
Oncotarget; 2017 Feb; 8(6):9696-9707. PubMed ID: 28039471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]